5th PPRI Conference - Programme

Day 1: Thursday, 25 April 2024 (09:00-17:30)

09.00-09.45: Welcome

  • Federal Minister of Social Affairs, Health, Care and Consumer Protection Johannes Rauch 
  • Executive Director Herwig Ostermann, Gesundheit Österreich GmbH (GÖG / Austrian National Public Health Institute) 
  • WHO Representative Klara Tisocki, Team Lead for Medicines and Health Products Pricing and Affordability in the Department of Health Products Policy, World Health Organization Headquarters
  • Head of WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies Sabine Vogler (GÖG / Austrian National Public Health Institute)

9.45-10.30: Keynote presentation: How to make medicines more accessible and affordable - From evidence to policy to practice

          Meindert Boysen, Head of International Affairs - National Institute for Health and Care Excellence (NICE), UK

10.30-11.00: Coffee break 

11.00-12.15: Stakeholder roundtable: Ensuring access to affordable medicines through innovative policies?

  • Johan Ponten, Dental and Pharmaceutical Benefits Agency (TLV), Sweden
  • Thomas Allvin, European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • Maja Graf, International Generic and Biosimilar Medicines Association (IGBA) 
  • Anca Toma, European Patients Forum
  • Giulia Segafredo, Medicines Patent Pool

Facilitator: Dimitra Panteli, European Observatory on Health Systems and Policies

12.15–12.30: Outlook on conference 

12.30-14.00: Lunch break

14.00-14:20: Keynote presentation: Can people afford to pay for health care? Evidence on financial protection in 40 countries in Europe

Tamás Evetovits and Sarah Thomson, WHO Barcelona Office for Health Systems Financing, Division of Country Health Policies and Systems 

14.30–15.30: Breakout session (Strand I – Strand III)

Strand I: Local challenges, global learnings?

  • Keynote presentation: Competition enforcement in the pharmaceutical sector - European competition authorities working together for affordable and innovative medicines (Leen De Vreese, European Commission, DG Competition)
  • Are competition fines effective deterrents to excessive pricing of medicines? Evidence from a landmark competition case in the United Kingdom (Melissa Barber, Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT), New Haven, USA)

Strand II: Strengthening the evidence base

  • Savings and Transparency: Comparing Publicly Reported Data on Managed Entry Agreements in Europe (Nora Franzen, Netherlands Cancer Institute, The Netherlands)
  • Investigating the Nature and Scope of Innovative Payment and Pricing Schemes for Health Technologies (Vittoria Ardito, Center for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Italy)

Strand III: Futureproofing pharmaceutical policies

  • Keynote presentation: Use of strategic approaches in public procurement of medicines: improving affordable patient access to medicines and protecting the environment in 32 European countries (Maximilian Salcher-Konrad, GÖG / Austrian National Public Health Institute)
  • Tendering of medically equivalent, patented outpatient pharmaceuticals (Hallstein Husbyn, Norwegian Medicines Agency)
  • First Nordic Tender with Environmental Criteria (Rasmus Syberg Hazelton, Amgros I/S, Denmark)

15.30–16.00: Poster walk during the coffee break

16.00 –16.45: Moderated poster session

Strand I: Local challenges, global learnings?

  • Early and compassionate access to medicines in France: two years after launch, what did and did not work? (Newfel Chekroun & Mayeul Charoy, Direction de la sécurité sociale, France) 
  • Selection of novel medicines for acute conditions versus chronic conditions on National Essential Medicines Lists compared to the WHO Model List (Moska Hellamand, WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, The Netherlands)
  • Evidence-based Decision-making Mechanism for Price Control of Biosimilars – A Study from India (Sonia Gandhi, Biotechnology Industry Research Assistance Council, Delhi, India)

Strand II: Strengthening the evidence base

  • Twelve years of European cancer drug approval—a systematic investigation of the ‘magnitude of clinical benefit’ (Nicole Grössmann-Waniek, HTA Austria - Austrian Institute for Health Technology Assessment GmbH)
  • Needs Examination, Evaluation and Dissemination (NEED): Towards a needs assessment framework and evidence database to support needs-driven innovation and policy in healthcare (Muriel Levy, Belgian Health Care Knowledge Centre (KCE), Brussels, Belgium
  • How to Price Advanced Therapies? Mixed approach for valuing a new CAR-T Cell for Multiple Myeloma in Brazil (Augusto Guerra, Collaborating Centre for Health Technology Assessment and Excellence (CCATES) / Postgraduate Program in Medicines and Pharmaceutical Assistance at the Federal University of Minas Gerais (PPGMAF/UFMG), Belo Horizonte, Brazil)

Strand III: Futureproofing pharmaceutical policies

  • Break on through (to the other side). A case study on increasing access to affordable CAR-T therapy through an academic hospital’s alternative innovation model (Adrian Alonso Ruiz, Global Health Centre, Graduate Institute of Development and International Studies, Switzerland)
  • Cost analysis of TB-PRACTECAL, a multicentre phase 2/3 trial in drug-resistant TB (Melissa Barber, Yale Collaboration for Regulatory Rigor, Integrity, and Transparency (CRRIT), New Haven, USA)
  • Using futures methods to think through financing for medicines R&D and issues of access (Sarah Parkinson, RAND Europe)

16.45-17.00: Reception

 

Day 2: Friday 26 April 2024 (09:00 - 16:00)

08.00-08.45: Early bird session: Meet the editors of journals in the pharmaceutical field

  • Journal of Pharmaceutical Policy and Practice (JOPPP), Zaheer-Ud-Din Babar
  • International Journal of Technology Assessment in Health Care, Claudia Wild 
  • Health Policy, Nathan Shuftan
  • Adis HEOR Journals (Applied Health Economics and Health Policy, Pharmacoeconomics, Pharmacoeconomics - Open), Tim Wrightson (video message)

9.00-09.30: Keynote presentation: WHO and Access to medicines - an update

          Sarah Garner, WHO Regional Office for Europe, Denmark

9.30-10.30: Country poster presentations

  • European Union
  • Other European Countries
  • Non-European Countries

10.30–11.00: Country poster walk during the coffee break

11.00–12.30: Breakout session (Strand I – III)

Strand I: Local challenges, global learnings?

  • Keynote presentation: Conceptual framework to build effective medicine pricing policies for low and middle-income countries (LMICs)
    Zaheer-Ud-Din Babar, University of Huddersfield, UK
  • Finland as a trailblazer in the uptake of less expensive biologic medicines – measures introduced in 2023 and 2024
    Kati Sarnola, Research at Kela, Social Insurance Institution of Finland (Kela), Helsinki, Finland
  • Alignment in the registration, selection, procurement and reimbursement of essential medicines for childhood cancers in South Africa
    Iris Joosse, WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, The Netherlands
  • Human normal immunoglobulin in Portugal: Analysing price increases across multiple markets
    Ana Correia, INFARMED – National Authority of Medicines and Health Products, I.P., Portugal

Strand II: Strengthening the evidence base

  • The desirability of implementing an outcome-based delayed payment model for autologous gene therapy atidarsagene autotemcel (Libmeldy®)
    Marcelien Callenbach, Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, The Netherlands
  • European comparison of prices for off-patent medicines – findings for 16 countries and implications for methodological choices
    Peter Schneider, GÖG / Austrian National Public Health Institute

Strand III: Futureproofing pharmaceutical policies

  • Keynote presentation: OECD’s quest for transparency in pharma markets - an update on recent contributions 
    Eliana Barrenho, OECD
  • Using AIM’s Fair Pricing Calculator for affordable and evidence-based pricing decisions, transitioning from policy concept to (inter-) national testing
    Thomas Kanga-Tona, International Association of Mutual Benefit Societies (AIM), Belgium
  • Disaggregation Of The Costs Of Pharmaceutical Research And Development
    Daniel Fabian, Austrian Institute of Health Technology Assessment
  • Unlocking global access to medicines for pandemics: the potential and limits of alternative innovation models
    Iulia Slovenski, Global Health Centre, Graduate Institute of International and Development Studies, Switzerland
     

12.30–13.30: Lunch

13.30-15.00: Conference workshops (parallel sessions)

  •  How the Euripid collaboration contributes to improving access to biosimilars 

    A workshop organised by the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomic Department, GÖG (Austrian National Public Health Institute) and the EURIPID collaboration 

    Facilitated by Claudia Habl (GÖG / Austrian National Public Health Institute, Secretary of the Board of Participants (BoP) of EURIPID)

    • Introduction of EURIPID and current EC Grant by project manager Gergely Németh (Semmelweis University, Hungarian National Health Insurance Fund, project manger of EURIPID)
    • Keynote: „Impact of market entries of biosimilars in Slovenia“ by Matjaž Marc (Agency for Medicinal Products and Medical Devices of the Slovenian Republic (JAZMP))
    • Plenary discussion on „Biosimilars – Monitoring & policies in the product life cycle management“ 
      • Francis Arickx (National Institute for Health and Disability Insurance (RIZIV-INAMI)) [online]
      • Liese Barbier (Katholieke Universiteit Leuven, European Medicines Agency (EMA))
      • Dorthe Barthels (AMGROS, Denmark)
      • Magnus Bodin (Chair of the Biosimilar Market Access Committee, Medicines for Europe and Head of International Access & Policy
    • Audience discussion (Q&A) 
  • Cross-border HTA partnerships and their role in sustainable access to medicines 
    A workshop organised by the Deloitte Health Economics and Outcomes Research Team Brussels and the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomic Department, GÖG (Austrian National Public Health Institute) 

    Facilitated by Burcak Aydin, Health Economics and Outcomes Research Team Brussels Deloitte

    • Keynote and panel discussion on cross-border HTA partnerships in Europe and beyond 
      • Dalia Dawoud, Associate Director, Science, Policy and Research Programme, National Institute for Health and Care Excellence (NICE), UK
      • Matteo Scarabelli, Associate Director, Market Access, EFPIA - European Federation of Pharmaceutical Industries and Associations
      • Anja Schiel, Norwegian Medical Products Agency
      • Anca Toma, European Patients Forum
    • Audience discussion (Q&A)
  • Access to new and expensive medicines in Austria: what role for the new "appraisal board"?
    A workshop organised by the WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies, Pharmacoeconomic Department, GÖG (Austrian National Public Health Institute)
    Facilitated by Maximilian Salcher-Konrad (GÖG / Austrian National Public Health Institute)
    • Presentation of the Austrian pharmaceutical system (Sabine Vogler, GÖG / Austrian National Public Health Institute)
    • Panel discussion on "Key challenges for affordable access to new medicines: what role for a new process for assessing selected new and expensive medicines in Austria?"
      • Sarah Mörtenhuber (Austrian Federal Ministry of Social Affairs, Health, Care and Consumer Protection)
      • Claas Röhl (patient representative; NF Kinder)
      • Nathanael Paterno (hospital payer; WIGEV / Vienna Healthcare Group)
      • Ronald Pichler (pharmaceutical industry; PHARMIG)
      • Invited commentary: Carolin Hagen (Norwegian Ministry of Health and Care Services)
    • Audience discussion (Q&A)

15.00-15.45: Keynote presentation: Action needed: Rediscovering Solidarity in Europe and beyond

         Anja Schiel, Senior Advisor, Norwegian Medicines Agency

15.45-16.00: Closing remarks, conclusions and awards